A Randomized, Placebo-Controlled, Phase 3 Study to Evaluate the Ability of a Novel Genomic Biomarker to Predict Survival of Treatment Naïve, High Risk Subjects with Diffuse Large B-Cell Lymphoma Treated with R-CHOP plus Enzastaurin